House
Sign inCreate account
Drug lookup
Drug reference

acalabrutinib

BTK inhibitor · Antineoplastic agent

BTK inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
  • AbciximabSevereDatabaseDDInter
  • AdalimumabSevereDatabaseDDInter
  • AlteplaseSevereDatabaseDDInter
  • AmprenavirSevereDatabaseDDInter

Mechanism

Acalabrutinib is a second-generation, orally bioavailable, irreversible BTK inhibitor that shows higher selectivity for BTK versus other kinases (e.g., EGFR, ITK) than ibrutinib. It inactivates BTK likely due to the covalent binding to a cysteine residue in the active site of the kinase.

Indications

MCL who have received at least one prior therapyCLLSLL

Pharmacokinetics

Half-life
1 h (acalabrutinib), 3.5 h (active metabolite)

Side effects

Common
lower rates of atrial fibrillation compared to ibrutiniblower rates of hypertension compared to ibrutiniblower rates of myalgias/arthralgias compared to ibrutiniblower rates of bruising compared to ibrutiniblower rates of skin and nail changes compared to ibrutinib
Serious
  • infections
  • hemorrhage
  • cytopenias
  • second primary malignancies (including nonmelanoma skin cancers)
  • cardiac arrhythmias

Pregnancy & lactation

Pregnancy

D

Drug interactions

Abciximab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Adalimumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Alteplase
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Amprenavir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Anagrelide
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Anisindione
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Anistreplase
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Antithrombin Alfa
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Antithrombin Iii Human
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Apalutamide
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Apixaban
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Aprepitant
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Related guidelines

Heart failure in diabetes
RSSDI · Cardiology · 2023
Hypertension in adults
ICMR · Cardiology · 2019
Hypertrophic cardiomyopathy
ESC · Cardiology · 2026
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022
Acute liver failure
ICMR · Gastroenterology · 2022

Other BTK inhibitor drugs

zanubrutinib
0 brands

Ask House about acalabrutinib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team